Where I'm Buying CPRXCatalyst Pharma (CPRX) is an absolute monster. Not only is the company posting huge sales and earnings growth in a sector that rarely has either, the stock has more than doubled over the last few months.
There are 801 stocks in the biotech group tracked by Investors Business Daily, and CPRX ranks at the very top (see image in chart).
After such a large advance higher, we must remain cautious to the possibility of a retracement. So we need to see signs of additional strength to trigger an entry.
I’m watching for a move above last week’s high for my buy signal. This way, I can place a stop below last week’s low and still get away with a risk of 8% or less on the trade.
Catalystpharmaceuticals
CPRX Catalyst Pharmaceuticals $40M Repurchase P/E Ratio 6.5 WOWCatalyst Pharmaceuticals is a biopharmaceutical company that specializes in therapies for rare neurological and neuromuscular diseases. It announced its fourth-quarter and 2020 financial results on March 15, 2021, reporting a 16% increase in revenue for fiscal 2020 and a 30% increase in operating income. (investopedia.com)
The company posted adjusted earnings of $0.11 per share, up 57% year-over-year, with the figure exceeding analysts’ expectations of $0.09 per share.
The company remains focused on acquiring or in-licensing innovative, technology platforms and early stage programs in therapeutic areas different from neuromuscular diseases. (smarteranalyst.com)
CPRX it`s an easy 50% in my opinion.
$40 Million Share Repurchase.
Market Cap 453.715M.
PE Ratio (TTM) 6.15.
75mil revenue, 119mil earnings in 2020
haven`t seen such a great balance sheet on a penny stock.
now trading at 4,94usd.
3/18/2021 Roth Capital Boost Price Target Buy $6.50 ➝ $7.00
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on the stock with a price target of $9
If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.